By Karen E. Roman
Sirnaomics Ltd., a biopharmaceutical company developing RNAi therapeutics, recently published a research article showing a cancer drug candidate to treat solid tumors.
The article focused on the company’s clinical studies with STP707, a polypeptide nanoparticle formulation, and provided a foundation for further research to treat hepatocellular carcinoma and other solid tumors, the company said.
“The newly described mechanism of action provides further scientific foundation for recent successes from our Phase I clinical study for STP707, as a single drug and, potentially, in combination with immune checkpoint inhibitors,” said Dr. Patrick Lu, Sirnaomics’ Chief Executive Officer.
Contact:
Editor@Executives-edge.com
